Please login to the form below

Not currently logged in

Vaccine developers call on FDA to offer clarity on COVID-19 trials

Comments from J&J and Pfizer made before FDA advisory committee meeting yesterday

Pfizer and Johnson & Johnson (J&J) have asked the US Food and Drug Administration (FDA) to provide clarity over retaining and attracting participants for COVID-19 vaccine trials after a vaccine becomes available to the public.

The comments were made in letters sent before an FDA advisory committee met yesterday to discuss issues relating to the development and authorisation of potential COVID-19 vaccines.

J&J urged the FDA committee to discuss the potential challenges of continuing trial enrolment in large-scale studies after the vaccines receive approval.

There is concern that individuals could be wary of enrolling in trials if they know they may receive a placebo shot as opposed to the COVID-19 vaccine.

Prior to the meeting, Pfizer officially asked the FDA if it could offer its vaccine candidate to participants in the placebo arm if their vaccine received approval, according to Endpoints News.

The committee debated what should be required to authorise or approve a COVID-19 vaccine and discussed the actions that the FDA had so far taken in the months since the pandemic began.

Within the discussions, some outside experts had doubts over the FDA guidelines recommending that a vaccine must have at least two months of safety data before being submitted for an emergency use authorisation (EUA).

Earlier this week, Pfizer’s chief executive officer Albert Bourla said that the company could submit an EUA for its BioNTech-partnered vaccine in the third week of November.

The company is awaiting a key data readout later this month, with Bourla adding that the company may know whether or not the vaccine is effective by October.

However, this depends on the number of COVID-19 cases in the phase 2/3 trial, which must reach a certain number in order to compare the effectiveness of the vaccine compared to placebo.

J&J, on the other hand, paused its COVID-19 vaccine study last week after a participant in its phase 3 study developed an unexplained illness.

Aside from confirming the participant illness, the company offered no further details regarding the nature of the adverse event and added that the vaccine study is not currently under clinical hold.

“We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information,” J&J added

Article by
Lucy Parsons

23rd October 2020

From: Regulatory



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...